We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Karus Therapeutics Extends Drug Discovery Programme to Target HDAC-6

Karus Therapeutics Extends Drug Discovery Programme to Target HDAC-6

Karus Therapeutics Extends Drug Discovery Programme to Target HDAC-6

Karus Therapeutics Extends Drug Discovery Programme to Target HDAC-6

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Karus Therapeutics Extends Drug Discovery Programme to Target HDAC-6"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Karus Therapeutics Ltd, a company engaged in the discovery and development of molecular-targeted drugs to treat inflammation and cancer, announced that it had extended its HDAC drug discovery programme to include small molecules that selectively inhibit HDAC-6, a target of emerging importance in the treatment of immune-inflammatory disorders.

The Company says that it has recently designed and developed a novel series of highly potent and selective HDAC-6 inhibitors which display excellent anti-inflammatory activity, notably in preclinical models of Rheumatoid Arthritis, and which have additional potential across a wide range of immune-inflammatory disorders.

Until recently, the development of HDAC inhibitors has been focused mainly on the treatment of cancer. However, there is a growing body of evidence from preclinical in vitro and in vivo models that the inhibition of HDAC-6 leads to increased expression of the FOXP3 transcription factor, a protein which plays a key role in the development and immunosuppressive function of regulatory T-cells in the context of chronic diseases such as Rheumatoid Arthritis, Psoriasis, Multiple Sclerosis, Lupus and Organ Transplant Rejection.

“There is a significant opportunity for the development of an important new class of anti-inflammatory drugs which selectively target HDAC-6.” said Karus Therapeutics CEO Simon Kerry “While HDAC inhibitors have been predominantly developed for use in oncology, our selective inhibitors of HDAC-6 have important anti-inflammatory and immunosuppressive qualities, which should translate into the effective treatment of a wide number of inflammatory indications and post-transplantation procedures.”

CSO Stephen Shuttleworth said: “The discovery and development of HDAC inhibitors with high levels of HDAC-6 selectivity has historically proven to be extremely challenging; there is currently a dearth of drug-like isoform-specific inhibitors and, therefore, a great demand for such molecules. We believe that the subtype-selective inhibitors developed at Karus represent a truly unique series of small molecule therapeutics with great potential in the treatment of chronic inflammatory diseases.”

HDAC-6 has also recently emerged as an important drug target in neurodegenerative disorders, including Alzheimer's Disease (AD), as well as stroke and spinal cord injury, and selective HDAC-6 inhibitors are expected to show promise as neuroprotectants in AD and related neurodegenerative diseases. Karus is currently undertaking additional proof-of-concept studies to assess the potential of its new class of HDAC-6 selective inhibitors in this clinical setting.